Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL

NCT04082897 is registered in ClinicalTrials.gov with Niguarda Hospital as lead sponsor.

NCT NCT04082897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04082897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Lead sponsor
Niguarda Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 4, 2019
Completion date
December 31, 2026
Enrollment
28 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cll transformation